查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1250772

到 2028 年的亨廷頓病治療市場預測——按療法（疾病修飾療法、對症治療）、藥劑、最終用戶和地區進行的全球分析

Huntington's Disease Treatment Market Forecasts to 2028 - Global Analysis By Treatment (Disease-modifying therapies and Symptomatic treatment), Drug, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年亨廷頓病治療的全球市場規模將達到 85 億美元，預計到 2028 年將達到 187 億美元，預測期內增長 14.1%。預計將以 CAGR 增長。

亨廷頓舞蹈症是一種罕見的遺傳性疾病，會導致大腦神經細胞進行性破壞，主要影響運動、情緒和認知能力。 在這種疾病中，大腦中的神經細胞發生故障並形成稱為神經原纖維纏結的蛋白質團塊，影響運動、思維、推理和情緒。 它會導致不受控制的運動和肌肉痙攣（霍亂）、語言模式改變、抑鬱、焦慮和性格改變。

根據美國亨廷頓病協會 (HDSA) 的數據，2021 年將有大約 41,000 名有症狀的美國人，超過 200,000 人有遺傳該病的風險。

市場動態

司機：

亨廷頓病的發病率增加

全球範圍內亨廷頓舞蹈病患病率的上升是推動市場增長的主要因素之一。 該程序經常用於停止不受控制的抽搐和跛行並改善生活質量。 此外，越來越多地採用臨床試驗、強大的藥物類型管道以及改進的醫療程序和療法預計將推動市場增長。

約束

缺乏批准的藥物和嚴格的監管政策

目前，只有兩種藥物被批准用於治療與這種疾病相關的角膜炎，而且這些藥物只能控制和抑制症狀，不能治癒疾病。 世界各地的公司要想批准藥品，就必須掃清嚴格的監管障礙。 此類監管限制可能會影響市場進入者的口味，導致預測期內市場增長放緩。

機會

激活研發

由於缺乏有效的治療方法和藥物，亨廷頓病的治療方法是一個廣闊的研究和開發領域。 預計這將在預測期內顯著促進市場增長。 此外，據推測，政府為促進新藥開發所做的努力也有望成為支持市場增長的因素之一。

威脅

藥物獲取困難

由於嚴格的政策法規，許可藥品的數量有限。 預計世界許多地區對這種疾病缺乏了解將限制市場擴張。 尋找治療這種疾病的藥物一直是一項重大挑戰，許多藥物未能證明療效或與顯著毒性有關。 預計這將阻礙市場增長。

COVID-19 的影響

預計 COVID-19 的爆發將對亨廷頓氏病治療的市場規模產生不利影響。 世界各地的大量診所和醫院正在重組以容納更多 COVID-19 患者。 患者人數的激增有時會減慢非必要任務的執行速度。 由於醫療保健所需物資的生產和交付受阻，它已經停止。 無法獲得醫療保健、醫療機構人員不足以及與 COVID-19 相關的住院率上升也是影響市場的其他變量。

在預測期內，疾病緩解療法領域預計將成為最大的領域

由於疾病緩解療法的研究和開發不斷增加，疾病緩解療法領域預計將實現有利增長。 靜脈內或口服給予的疾病緩解療法可以減輕當前症狀或減緩進展。 疾病改善療法可以改善與這種疾病相關的問題，例如精神障礙和抑鬱症，但尚未顯示可以改變患者死亡率。

抗抑鬱藥細分市場有望在預測期內實現最高複合年增長率

預計抗抑鬱藥在預測期內將以最快的複合年增長率增長，因為它們旨在恢復精神穩定性。 抗抑鬱藥是改善臨床抑鬱症、聽力損失、社交焦慮、焦慮和其他症狀的處方藥。 抗抑鬱藥治療主要集中在緩解嚴重抑鬱症的症狀上。 這些是該領域增長的驅動力。

市場份額最高的地區

由於這種疾病的患病率相對較低，預計亞太地區在預測期內將佔據最大的市場份額。 然而，在預測期內，這些地區改進的報銷政策以及患者對可用治療的認識提高，預計將有助於增長前景。

複合年增長率最高的地區：

由於產品滲透率不斷提高，預計北美在預測期內的複合年增長率最高。 公眾對該疾病的認識很高，許多公共和私人組織的研究資金和支持正在促進對該疾病的研究。 隨著各國政府加緊努力改善其人口的健康，預計該地區的市場將會增長。

主要市場參與者

亨廷頓氏病治療市場的主要參與者包括Novartis AG、Teva Pharmaceutical Industries Ltd.、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries, Inc.、Lupin、Hetero、Hikma Pharmaceuticals PLC、Bausch Health Companies Inc.、 Alterity Therapeutics、H. Lundbeck A/S、Neurocrine Biosciences, Inc.、Annexon Biosciences、PTC Therapeutics、Prilenia Therapeutics、Amneal Pharmaceuticals LLC.、SOM BIOTECH、Vertex Pharmaceuticals Incorporated。

主要發展：

2021 年 12 月，Novartis AG 獲得了 FDA 對 Branaplam 治療亨廷頓舞蹈病的快速通道指定。 Branaplam 是一種 mRNA 剪接調節劑，其靶向 HTT 蛋白，該蛋白負責引起導致亨廷頓舞蹈病的神經元變性。

2021 年 10 月，Teva Pharmaceutical Industries Limited 獲得了在巴西治療與亨廷頓舞蹈症相關的角膜炎和遲發性運動障礙的上市許可。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會/建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 對其他市場參與者（最多 3 個）進行全面分析
    • 主要參與者的 SWOT 分析（最多 3 人）
  • 區域細分
    • 應客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：通過可行性檢查）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球亨廷頓病治療市場：按治療分類

  • 疾病緩解療法
  • 對症治療

第 6 章全球亨廷頓病治療市場：按代理

  • 抗抑鬱藥
  • 抗精神病藥
  • 鎮靜劑
  • 丁苯那秦
  • 其他藥物

第 7 章。全球亨廷頓病治療市場：按最終用戶分類

  • 醫務室
  • 醫院
  • 零售藥房
  • 在線藥店
  • 其他最終用戶

第 8 章。全球亨廷頓病治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第九章主要進展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第十章公司簡介

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Lupin
  • Hetero
  • Hikma Pharmaceuticals PLC
  • Bausch Health Companies Inc.
  • Alterity Therapeutics
  • H. Lundbeck A/S
  • Neurocrine Biosciences, Inc.
  • Annexon Biosciences
  • PTC Therapeutics
  • Prilenia Therapeutics
  • Amneal Pharmaceuticals LLC.
  • SOM BIOTECH
  • Vertex Pharmaceuticals Incorporated
Product Code: SMRC22649

According to Stratistics MRC, the Global Huntington's Disease Treatment Market is accounted for $8.5 billion in 2022 and is expected to reach $18.7 billion by 2028 growing at a CAGR of 14.1% during the forecast period. Huntington's disease is a rare inherited disease that causes progressive breakdown of nerve cells in the brain, mainly affecting physical movements, emotions and cognitive abilities. It is a condition in which the nerve cells of the brain malfunction and create clumps of a protein called neurofibrillary tangles that affect movement, thinking, reasoning, moods, and more. It can cause uncontrolled movements or muscle twitches (chorea), changes in speech patterns, depression, anxiety, and personality changes.

According to the Huntington's disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease.

Market Dynamics:

Driver:

The rising incidence of Huntington's disease

The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. The procedure is frequently used to stop uncontrollable jerking and writhing motion, which enhances quality of life. In addition, clinical trials, strong drug type pipeline and growing adoption of improved medical treatments and therapies are expected to fuel the market growth.

Restraint:

Lack of approved drugs and stringent regulatory policies

Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs. Such regulatory limits may impact market participants' preferences, resulting in slower market growth during the projection period.

Opportunity:

Growing research and development activities

There is a vast area of research and development for Huntington's disease treatment approaches because there is no effective treatment or medication. This is expected to significantly boost market growth during the forecast period. Moreover, the promising government initiatives that promote the development of new drugs are estimated to be another factor supporting the market growth.

Threat:

Limited availability of drugs

The number of licensed pharmaceuticals is limited due to tight policies and restrictions. It is anticipated that the market's expansion will be constrained by the lack of knowledge about this illness in many regions of the world. Many medications have failed to show efficacy or have been linked to significant toxicity, which has presented significant challenges for the discovery of drugs to treat the disease. This is expected to hamper the market growth.

Covid-19 Impact

The COVID-19 outbreak is projected to have a detrimental effect on the size of the market for treating Huntington's disease. To accommodate more patients with COVID-19, a sizable number of clinics and hospitals around the world underwent restructuring. Because of the sharp increase in patients, non-essential operations could be delayed. Production and delivery of supplies for healthcare were halted as a result of the lockdown. Lack of access to healthcare, a staffing deficit in the medical field, and an increase in COVID-19-related hospitalisation are some additional variables that have an impact on the market.

The disease-modifying therapies segment is expected to be the largest during the forecast period

The disease-modifying therapies segment is estimated to have a lucrative growth, due to an increase in disease-modifying therapy R&D. They can be administered intravenously or orally to lessen current symptoms or slow their progression. Disease-modifying therapies can help with problems like psychological illnesses and depression linked to this condition, but they have not been found to change patient mortality rates.

The antidepressants segment is expected to have the highest CAGR during the forecast period

The antidepressants segment is anticipated to witness the fastest CAGR growth during the forecast period, due to they are intended to restore the mental stability. Antidepressants are prescription medications that can help with symptoms of clinical depression, dysthymia, social anxiety, anxiety, and other conditions. Treatment with antidepressants focuses primarily on reducing the symptoms of severe depression. These are driving the segment growth.

Region with Largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the comparatively lower prevalence rate of this condition amongst the population. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing product penetration. A high level of public awareness about the condition, as well as growing support from numerous public and private organisations through research funding, to expedite the study of this disease. As governments take more initiatives to improve the health status of the populations, the market in the region is expected to grow.

Key Players in the market

Some of the key players profiled in the Huntington's Disease Treatment Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Lupin, Hetero, Hikma Pharmaceuticals PLC, Bausch Health Companies Inc., Alterity Therapeutics, H. Lundbeck A/S, Neurocrine Biosciences, Inc., Annexon Biosciences, PTC Therapeutics, Prilenia Therapeutics, Amneal Pharmaceuticals LLC., SOM BIOTECH and Vertex Pharmaceuticals Incorporated.

Key Developments:

In December 2021, Novartis AG received Fast Track designation for Branaplam from the FDA for Huntington's disease treatment. Branaplam is an mRNA splicing modulator that targets the HTT protein responsible for causing the degeneration of nerve cells leading to Huntington's disease.

In October 2021, Teva Pharmaceutical Industries Ltd. Received marketing approval for the treatment of chorea associated with Huntington's disease treatment and for the treatment of tardive dyskinesia in Brazil.

Treatments Covered:

  • Disease-modifying therapies
  • Symptomatic treatment

Drugs Covered:

  • Antidepressants
  • Antipsychotic Drugs
  • Tranquilizers
  • Tetrabenazine
  • Other Drugs

End Users Covered:

  • Clinics
  • Hospital
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Huntington's Disease Treatment Market, By Treatment

  • 5.1 Introduction
  • 5.2 Disease-modifying therapies
  • 5.3 Symptomatic treatment

6 Global Huntington's Disease Treatment Market, By Drug

  • 6.1 Introduction
  • 6.2 Antidepressants
  • 6.3 Antipsychotic Drugs
  • 6.4 Tranquilizers
  • 6.5 Tetrabenazine
  • 6.6 Other Drugs

7 Global Huntington's Disease Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Clinics
  • 7.3 Hospital
  • 7.4 Retail Pharmacies
  • 7.5 Online Pharmacies
  • 7.6 Other End Users

8 Global Huntington's Disease Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis AG
  • 10.2 Teva Pharmaceutical Industries Ltd.
  • 10.3 Dr. Reddy's Laboratories Ltd.
  • 10.4 Sun Pharmaceutical Industries, Inc.
  • 10.5 Lupin
  • 10.6 Hetero
  • 10.7 Hikma Pharmaceuticals PLC
  • 10.8 Bausch Health Companies Inc.
  • 10.9 Alterity Therapeutics
  • 10.10 H. Lundbeck A/S
  • 10.11 Neurocrine Biosciences, Inc.
  • 10.12 Annexon Biosciences
  • 10.13 PTC Therapeutics
  • 10.14 Prilenia Therapeutics
  • 10.15 Amneal Pharmaceuticals LLC.
  • 10.16 SOM BIOTECH
  • 10.17 Vertex Pharmaceuticals Incorporated

List of Tables

  • Table 1 Global Huntington's Disease Treatment Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 3 Global Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 4 Global Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 5 Global Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 6 Global Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 7 Global Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 8 Global Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 9 Global Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 10 Global Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 11 Global Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 12 Global Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 13 Global Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 14 Global Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 15 Global Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 16 Global Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 17 North America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 18 North America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 19 North America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 20 North America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 21 North America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 22 North America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 23 North America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 24 North America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 25 North America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 26 North America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 27 North America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 28 North America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 29 North America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 30 North America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 31 North America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 32 North America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 33 Europe Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 34 Europe Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 35 Europe Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 36 Europe Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 37 Europe Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 38 Europe Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 39 Europe Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 40 Europe Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 41 Europe Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 42 Europe Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 43 Europe Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 44 Europe Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 45 Europe Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 46 Europe Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 47 Europe Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 48 Europe Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 49 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 50 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 51 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 52 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 53 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 54 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 55 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 56 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 57 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 58 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 59 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 60 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 61 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 62 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 63 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 64 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 65 South America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 66 South America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 67 South America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 68 South America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 69 South America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 70 South America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 71 South America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 72 South America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 73 South America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 74 South America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 75 South America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 76 South America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 77 South America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 78 South America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 79 South America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 80 South America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 81 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 83 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 84 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 85 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 86 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 87 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 88 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 89 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 90 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 91 Middle East & Africa Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 92 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 93 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 94 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 95 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 96 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)